{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:13:25Z","timestamp":1763018005365},"reference-count":81,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"paper"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2019,7,3]]},"DOI":"10.1080\/14712598.2019.1604672","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T14:47:27Z","timestamp":1557758847000},"page":"707-720","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs"],"prefix":"10.1080","volume":"19","author":[{"given":"Laahn H.","family":"Foster","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence G.","family":"Lum","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Virginia, Charlottesville, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,5,13]]},"reference":[{"issue":"6","key":"CIT0001","first-page":"2073","volume":"41","author":"Raso V","year":"1981","journal-title":"Cancer Res"},{"issue":"9","key":"CIT0002","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4049\/jimmunol.139.9.3153","volume":"139","author":"Titus JA","year":"1987","journal-title":"J Immunol"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1089\/15258160151134944"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2280"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/285193"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4108"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24237"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.133"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.03.010"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.030"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2013.08.007"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2010.04.001"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306449"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0350"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23626"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31370"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25354"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377713"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-798322"},{"key":"CIT0029","doi-asserted-by":"crossref","unstructured":"Salogub G, Mayer J, Folber F, et al. A phase 1 study investigating AFM11 in patients with relapsed\/refractory B cell precursor acute lymphoblastic leukemia: preliminary results. Blood. 2018;132(suppl 1):3969.","DOI":"10.1182\/blood-2018-99-118136"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135945"},{"issue":"18","key":"CIT0031","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S1359-6446(05)03554-3","volume":"10","author":"Walter RB","year":"2005","journal-title":"Drug Discov Today"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523548"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03554-3"},{"issue":"116","key":"CIT0034","first-page":"1","volume":"6","author":"Jitschin R","year":"2018","journal-title":"J Immunother Cancer"},{"key":"CIT0035","doi-asserted-by":"crossref","unstructured":"Ravandi F, Stein S, Kantarjian H, et al. First-in-human study of AMG 330, an anti-CD33 bispecific T-cell engager (BiTE \u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML). Blood. 2018;132(suppl 1):25.","DOI":"10.1182\/blood-2018-99-109762"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014373"},{"key":"CIT0037","doi-asserted-by":"crossref","unstructured":"Westervelt P, Roboz G, Cortes J, et al. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2\u00a0\u00d7\u00a02) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2018;132(suppl 1):1455.","DOI":"10.1182\/blood-2018-99-111529"},{"issue":"12","key":"CIT0038","first-page":"1261","volume":"86","author":"Mu\u00f1oz L","year":"2001","journal-title":"Haematologica"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0852"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-575704"},{"key":"CIT0041","doi-asserted-by":"crossref","unstructured":"Uy GL, Rettig MP, Godwin J, et al. Phase 1 cohort expansion of flotetuzumab, a CD123 \u00d7 CD3 bispecific dart \u00ae protein in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2018;132(suppl 1);764.","DOI":"10.1182\/blood-2018-99-117085"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119786"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-083048"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201405353"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-735365"},{"key":"CIT0046","doi-asserted-by":"crossref","unstructured":"Liu F, Cao Y, Pinz K, et al. First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia : update on phase 1 clinical trial. Blood. 2018;132(suppl 1):901.","DOI":"10.1182\/blood-2018-99-110579"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.267"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2710"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012369"},{"key":"CIT0050","doi-asserted-by":"crossref","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010 Apr;47(2):115\u2013123.","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13242"},{"key":"CIT0052","first-page":"1","volume":"5","author":"Smith EJ","year":"2015","journal-title":"Sci Rep"},{"key":"CIT0053","doi-asserted-by":"crossref","unstructured":"Bannerji R, Ufkin M, Yan X, et al. Emerging clinical activity of REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (follicular lymphoma, diffuse large B-cell lymphoma, and other B-cell non-Hodgkin lymphoma. Blood. 2018;132(suppl 1):1690.","DOI":"10.1182\/blood-2018-99-113328"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118344"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1836.1836"},{"key":"CIT0056","author":"Hutchings M","journal-title":"Blood. 2018"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.1586"},{"issue":"21","key":"CIT0058","first-page":"no pagination","volume":"124","author":"Viardot A","year":"2016","journal-title":"Blood"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05482.x"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-1984"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2999.2999"},{"key":"CIT0064","doi-asserted-by":"crossref","unstructured":"Topp MS, Duell J, Zugmaier G, et al. Treatment with AMG 420, an anti-B-cell maturation antigen (BCMA) bispecific T-cell engager (BiTE \u00c2 \u00ae) antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and\/or refractory (R\/R) multiple myeloma. Blood. 2018;132(suppl 1):1010.","DOI":"10.1182\/blood-2018-99-109769"},{"key":"CIT0065","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Raje N, Gasparetto CJ, et al. A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-cell maturation antigen\/CD3 bispecific antibody, in patients with relapsed\/refractory advanced multiple myeloma. Blood. 2018;132(suppl 1):3229.","DOI":"10.1182\/blood-2018-99-110427"},{"key":"CIT0066","doi-asserted-by":"crossref","unstructured":"Dilillo DJ, Olson K, Mohrs K, et al. REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor Efficacy in multiple myeloma models, comparable to that of BCMA CAR T cells. Blood. 2018;132(suppl 1):1944.","DOI":"10.1182\/blood-2018-99-112500"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3111.3111"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.04.003"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2008.02.004"},{"key":"CIT0070","first-page":"8","volume":"13","author":"Spear P","year":"2013","journal-title":"Cancer Immun"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2125"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0649"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1062192"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1095"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.175"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1386361"},{"issue":"1","key":"CIT0077","volume":"130","author":"Boyd-Kirkup J","year":"2017","journal-title":"Blood"},{"key":"CIT0078","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.214"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.68"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-849802"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2769"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2019.1604672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T14:38:14Z","timestamp":1694875094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2019.1604672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,13]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,3]]}},"alternative-id":["10.1080\/14712598.2019.1604672"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2019.1604672","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}